PT - JOURNAL ARTICLE AU - Paola A. Erba AU - Martina Sollini AU - Enrico Orciuolo AU - Claudio Traino AU - Mario Petrini AU - Giovanni Paganelli AU - Emilio Bombardieri AU - Chiara Grana AU - Leonardo Giovannoni AU - Dario Neri AU - Hans D. Menssen AU - Giuliano Mariani TI - Radioimmunotherapy with Radretumab in Patients with Relapsed Hematologic Malignancies AID - 10.2967/jnumed.111.101006 DP - 2012 Jun 01 TA - Journal of Nuclear Medicine PG - 922--927 VI - 53 IP - 6 4099 - http://jnm.snmjournals.org/content/53/6/922.short 4100 - http://jnm.snmjournals.org/content/53/6/922.full SO - J Nucl Med2012 Jun 01; 53 AB - We present here a systematic analysis of lymphoma and MM patients recruited into 2 clinical trials or treated with radretumab according to compassionate use, describing the biodistribution, dosimetry, safety, and clinical activity of radretumab. Methods: Uptake in lymphoma lesions, safety, and clinical activity of radretumab radioimmunotherapy (R-RIT) were evaluated in 18 relapsed lymphoma or multiple myeloma patients. Results: In 14 of 18 patients, selective tumor uptake was found; 11 of 15 lymphoma patients, including 9 of 11 with Hodgkin lymphoma (HL), were eligible for R-RIT (a priori criteria–based target-to-bone marrow ratio > 10:1 for EudraCT no. 2005-000545 or > 4:1 for EudraCT no. 2007-007241-12 at dosimetric imaging). Two HL and 1 diffuse large B cell lymphoma patient achieved complete response; 1 HL patient had partial response. Both multiple myeloma patients receiving R-RIT experienced stabilization of disease. Therefore, the overall objective response rate was 40%. Uncomplicated grade 3–4 thrombocytopenia or leukocytopenia was observed in 5 R-RIT patients, lasting 4–129 d. Conclusion: R-RIT showed a favorable benefit and risk profile in advanced relapsed lymphoma patients and induced complete response in 2 heavily pretreated, relapsed HL patients and in 1 diffuse large B cell lymphoma patient. These results warrant further exploration of R-RIT in larger phase II clinical trials.